LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Manufacturing Facility
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • IR Inquiries
Mechanism of treatment for cartilage regeneration using stem cells, the first in the world
2013/06/23
STEM CELL THERAPEUTIC

MEDIPOST, will do research into the promotion of cartilage cell division by a specific protein…published in Stem Cell

A Korean group of researchers have found that a specific protein can promote the division of cartilage.

MEDIPOST has stated that the study on ‘The Mechanism of cartilage regeneration treatment using stem cells’ was published in one of the top journals in stem cell research, Stem Cell, on July 23.

MEDIPOST has produced results that the administration of mesenchymal stem cells extracted from the cord into the damaged knee joints of animals led to precursor cartilage cell division by various proteins, including TSAP-2, and published these results.

This study is meaningful in the era of various stem cell researches into cartilage regeneration treatment, because it has tested the hypothesis that ‘stem cells do not directly become cartilage cells, but rather, secrete specific proteins to induce cartilage production’.

The utilization of these results can lead to adjustment of the level of secretion of effective proteins within the stem cell treatment agent, or develop the optimal administration route and method, which can improve the success rate of cartilage regeneration treatment.

Stem Cell, which is where this study was published in, is one of the oldest and well known journals, with a SCI factor and IF of 7.701.

The related person from MEDIPOST said that ‘the publication of this study is to scientifically prove the mechanism of action of ‘CARTISTEM’ and have it recognized by the world’, and added, ‘this will hopefully lead to vitalization of cartilage-related research and the development of second generation CARTISTEM’.

VIEW LIST

Related News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022/07/18

Latest News

MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.
2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge
2022/10/17
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy
2022/10/07
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award
2022/07/18
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products
2022/05/31

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

CS CENTER
ONLINE INQUIRY

Latest News

·
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022.12.01
·
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022.10.17
·
Canada’s OmniaBio, MEDIPOST affiliate begins CDMO cGMP for cell gene therapy2022.10.07
·
MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award2022.07.18
·
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022.05.31

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST